These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 23556074)

  • 1. The revolution of myelodysplastic syndromes.
    Sekeres MA; Bejanyan N
    Ther Adv Hematol; 2011 Feb; 2(1):33-43. PubMed ID: 23556074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies.
    Komrokji R; Swern AS; Grinblatt D; Lyons RM; Tobiasson M; Silverman LR; Sayar H; Vij R; Fliss A; Tu N; Sugrue MM
    Oncologist; 2018 Feb; 23(2):159-170. PubMed ID: 29118268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Approaches to Myelodysplastic Syndrome Treatment.
    Bazinet A; Bravo GM
    Curr Treat Options Oncol; 2022 May; 23(5):668-687. PubMed ID: 35320468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment for low-risk myelodysplastic syndromes].
    Morita Y
    Rinsho Ketsueki; 2018; 59(10):2050-2057. PubMed ID: 30305508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypomethylating agents and other novel strategies in myelodysplastic syndromes.
    Garcia-Manero G; Fenaux P
    J Clin Oncol; 2011 Feb; 29(5):516-23. PubMed ID: 21220589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis and Treatment of Myelodysplastic Syndromes: A Review.
    Sekeres MA; Taylor J
    JAMA; 2022 Sep; 328(9):872-880. PubMed ID: 36066514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal sequencing of treatments for patients with myelodysplastic syndromes.
    Itzykson R; Fenaux P
    Curr Opin Hematol; 2009 Mar; 16(2):77-83. PubMed ID: 19468268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
    Nimer SD
    J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myelodysplastic syndromes: a review of therapeutic progress over the past 10 years.
    Feld J; Belasen A; Navada SC
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):465-482. PubMed ID: 32479130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS).
    Almeida A; Fenaux P; List AF; Raza A; Platzbecker U; Santini V
    Leuk Res; 2017 Jan; 52():50-57. PubMed ID: 27883945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes.
    Sekeres MA; Maciejewski JP; Giagounidis AA; Wride K; Knight R; Raza A; List AF
    J Clin Oncol; 2008 Dec; 26(36):5943-9. PubMed ID: 19018091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel therapeutic strategies: hypomethylating agents and beyond.
    Santini V
    Hematology Am Soc Hematol Educ Program; 2012; 2012():65-73. PubMed ID: 23233562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
    Garcia-Manero G
    Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment options for lower-risk myelodysplastic syndromes. Where are we now?
    Volpe VO; Komrokji RS
    Ther Adv Hematol; 2021; 12():2040620720986641. PubMed ID: 33505645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States.
    Ma X; Steensma DP; Scott BL; Kiselev P; Sugrue MM; Swern AS
    BMJ Open; 2018 Jul; 8(7):e019955. PubMed ID: 30037860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myelodysplastic syndromes: Contemporary review and how we treat.
    Gangat N; Patnaik MM; Tefferi A
    Am J Hematol; 2016 Jan; 91(1):76-89. PubMed ID: 26769228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Established and novel agents for myelodysplastic syndromes.
    Sekeres MA; Gerds AT
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):82-9. PubMed ID: 25696839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The lower risk MDS patient at risk of rapid progression.
    Mittelman M; Oster HS; Hoffman M; Neumann D
    Leuk Res; 2010 Dec; 34(12):1551-5. PubMed ID: 20573398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
    Park S; Hamel JF; Toma A; Kelaidi C; Thépot S; Campelo MD; Santini V; Sekeres MA; Balleari E; Kaivers J; Sapena R; Götze K; Müller-Thomas C; Beyne-Rauzy O; Stamatoullas A; Kotsianidis I; Komrokji R; Steensma DP; Fensterl J; Roboz GJ; Bernal T; Ramos F; Calabuig M; Guerci-Bresler A; Bordessoule D; Cony-Makhoul P; Cheze S; Wattel E; Rose C; Vey N; Gioia D; Ferrero D; Gaidano G; Cametti G; Pane F; Sanna A; Germing U; Sanz GF; Dreyfus F; Fenaux P
    J Clin Oncol; 2017 May; 35(14):1591-1597. PubMed ID: 28350519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel therapies in low- and high-risk myelodysplastic syndrome.
    Germing U; Schroeder T; Kaivers J; Kündgen A; Kobbe G; Gattermann N
    Expert Rev Hematol; 2019 Oct; 12(10):893-908. PubMed ID: 31353975
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.